journal cover

Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU

Biochemical Pharmacology

May 15, 2005

Kevin P RiceAlan C Sartorelli

Get paper from

Abstract

The antitumor, DNA-alkylating agent 1,3-bis[2-chloroethyl]-2-nitrosourea (BCNU; Carmustine), which generates 2-chloroethyl isocyanate upon decomposition in situ, inhibits cellular glutathione reductase (GR; EC 1.8.1.7) activity by up to 90% at pharmacological doses. GR is susceptible to...read more

Mentioned in this Paper

Synergism
Cysteine
Enzymes, antithrombotic
Glutathione Reductase
Enzymes, peripheral vasodilators
Antineoplastic Agents
2-hydroxyethyl disulfide
Inactivation
Centrifugation
Intestines
5
Paper Details
References
  • References25
  • Citations20
123
  • References25
  • Citations20
12

Similar Papers Found In These Feeds

Myelodysplastic Syndromes

Myelodysplastic syndromes are cancers in which immature blood cells in the bone marrow do not mature to become healthy blood cells. Discover the latest research on this cancer here.

Sulfonamides

Sulfonamide is a functional group found as the base of several classes of drugs. Sulfonamides can act as synthetic antimicrobial agents, anti-diabetics, diuretics, anticonvulsants, etc. Here is the latest research.

Drug-Induced Diseases

Drug-induced diseases (DID) also called as iatrogenic diseases. Most of these DIDs are largely preventable, if strict vigilance and proper periodic clinical and diagnostic monitoring are undertaken

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2019 Meta ULC. All rights reserved

Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU

Biochemical Pharmacology

May 15, 2005

Kevin P RiceAlan C Sartorelli

PMID: 15857610

DOI: 10.1016/j.bcp.2005.02.016

Abstract

The antitumor, DNA-alkylating agent 1,3-bis[2-chloroethyl]-2-nitrosourea (BCNU; Carmustine), which generates 2-chloroethyl isocyanate upon decomposition in situ, inhibits cellular glutathione reductase (GR; EC 1.8.1.7) activity by up to 90% at pharmacological doses. GR is susceptible to...read more

Mentioned in this Paper

Synergism
Cysteine
Enzymes, antithrombotic
Glutathione Reductase
Enzymes, peripheral vasodilators
5

Related Papers

Paper Details
References
  • References25
  • Citations20
123
  • References25
  • Citations20
12

Get paper from

/papers/differential-inhibition-of-cellular-glutathione/15857610